Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 7/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961811 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 | |
| SCHEMBL13481196 | 0.71 | CYP17A1 (0.50) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 | |
| SCHEMBL5345134 | 0.70 | CYP17A1 (0.49) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 | |
| SCHEMBL5618398 | 0.70 | CYP17A1 (0.49) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 | |
| SCHEMBL8404486 | 0.69 | SMN1; SMN2 (0.53) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 | |
| Hydrochloric Acid SCHEMBL6996249 | 0.69 | CYP17A1 (0.48) | SMN1; SMN2FFAR1CYP17A1SSTR4 | |
| SCHEMBL6987832 | 0.66 | SMN1; SMN2 (0.54) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 | |
| SCHEMBL1759529 | 0.66 | SMN1; SMN2 (0.54) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 | |
| SCHEMBL4572282 | 0.66 | SMN1; SMN2 (0.50) | SMN1; SMN2FFAR1CYP1A2SSTR4MCL1 | |
| SCHEMBL12946371 | 0.64 | SMN1; SMN2 (0.47) | SMN1; SMN2FFAR1CYP17A1CYP1A2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057956-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | SMN1; SMN2 1624/4885FFAR1 2040/4885CYP17A1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.